Liver fibrosis in a comorbid patient with metabolicassociated (non-alcoholic) fatty liver disease (MAFLD-NAFLD) and cardiovascular disease

Abstract

The aim of this review is to systematise the available evidence on the comorbid course of non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease, assessing the role of liver fibrosis in patient prognosis. Discussion: the criteria for the diagnosis of metabolic-associated liver disease (MAFLD) in comparison with non-alcoholic fatty liver disease (NAFLD) were presented. The results of studies demonstrating the close relationship of NAFLD and NAFLD with the development of cardiovascular diseases were occurred. The underlying factor tending the cardiovascular risk of patients with NAFLD and MAFLD is liver fibrosis. Invasive and non-invasive methods for the diagnosis of liver fibrosis in NAFLD were discussed. The evidence of the expediency and safety of the use of statins in this pathology was presented. Conclusion: according to the pandemic growth of NAFLD and its association with cardiovascular risk, the question of how to properly monitor patients with comorbid cardiovascular diseases and NAFLD in order to reduce the risks is timely and very relevant. One of the main prognostic risk factors for an unfavorable outcome in this category of patients is liver fibrosis. Lipid-lowering therapy seems to be the most optimal and safe treatment strategy for these patients.